Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Biogen Inc. (BIIB) shares rallied 5.7% in the last trading session to close at $120.49. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold. Analyst Price Forecast Suggests 63.45% Upside As of April 1, 2025, the ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

SG Americas Securities, LLC has opened a new $98.5M position in $BIIB, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 ...

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. According to ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...